Unity Biotechnology (UBX) Stock Forecast & Price Target

$1.42

+0.01 (+0.71%)

(As of 09/17/2024 ET)

Unity Biotechnology - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 3 Analyst Ratings

Based on 3 Wall Street analysts who have issued ratings for Unity Biotechnology in the last 12 months, the stock has a consensus rating of "Buy." Out of the 3 analysts, 3 have given a buy rating for UBX.

Consensus Price Target

$6.67
369.48% Upside

High Forecast	$8.00
Average Forecast	$6.67
Low Forecast	$4.00

According to the 3 analysts' twelve-month price targets for Unity Biotechnology, the average price target is $6.67. The highest price target for UBX is $8.00, while the lowest price target for UBX is $4.00. The average price target represents a forecasted upside of 369.48% from the current price of $1.42.

Type	Current Forecast 9/18/23 to 9/17/24	1 Month Ago 8/19/23 to 8/18/24	3 Months Ago 6/20/23 to 6/19/24	1 Year Ago 9/18/22 to 9/18/23
Consensus Rating	Buy	Buy	Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)	3 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$6.67	$6.00	$6.00	$6.75
Forecasted Upside	369.48% Upside	270.37% Upside	256.08% Upside	210.45% Upside

Is A Starlink IPO Coming In 2024? (Ad)

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.

Click here now for the urgent details on this hidden play.

UBX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

UBX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Unity Biotechnology Stock vs. The Competition

Type	Unity Biotechnology	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.77	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	369.48% Upside	1,008.89% Upside	7.65% Upside
News Sentiment Rating	Very Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/22/2024	Rodman & Renshaw 1 of 5 stars		Initiated Coverage	Buy	$8.00	+422.87%
8/8/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00	+467.37%
11/16/2023	Wedbush 3 of 5 stars	A. Argyrides Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$4.00	+118.58%
5/26/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$5.00 ➝ $6.00	+120.59%
3/28/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$12.00 ➝ $6.00	+207.69%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:41 PM ET.

UBX Forecast - Frequently Asked Questions

What is Unity Biotechnology's forecast for 2024?: According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Unity Biotechnology is $6.67, with a high forecast of $8.00 and a low forecast of $4.00.
Should I buy or sell Unity Biotechnology stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" UBX shares.
Does Unity Biotechnology's stock price have much upside?: According to analysts, Unity Biotechnology's stock has a predicted upside of 319.29% based on their 12-month stock forecasts.
What analysts cover Unity Biotechnology?: Unity Biotechnology has been rated by research analysts at HC Wainwright, and Rodman & Renshaw in the past 90 days.
Do Wall Street analysts like Unity Biotechnology more than its competitors?: Analysts like Unity Biotechnology more than other "medical" companies. The consensus rating for Unity Biotechnology is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how UBX compares to other companies.